Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.44 |
| ▸ | PGR | P06401 | 4/20 | 0.44 |
| ▸ | AR | P10275 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29227574 | 0.84 | MEN1 (0.43) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL10896733 | 0.81 | CYP3A4 (0.62) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL28374127 | 0.80 | MEN1 (0.47) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL10389248 | 0.78 | CYP3A4 (0.39) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL29882740 | 0.78 | CYP3A4 (0.66) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL13981881 | 0.78 | CYP3A4 (0.66) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL369752 | 0.78 | CYP3A4 (0.66) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL18402585 | 0.78 | CYP3A4 (0.66) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL1635633 | 0.77 | CYP19A1 (0.48) | CYP3A4PGRARALDH1A1CHRM1 | |
| SCHEMBL3028086 | 0.77 | CYP19A1 (0.48) | CYP3A4PGRARALDH1A1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113976113-B | Catalyst for synthesis of megestrol acetate, preparation method and application thereof | 西安凯立新材料股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-7932382-B2 | Amide substituted heterocylic compound; anticarcinogen; inducing apoptotic cell death, sensitizing cells to inducers of apoptosis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090082445-A1 | GOSSYPOL CO-CRYSTALS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2009-03-26 | — | — | US | disclosed |
| WO-2008148473-A2 | METHOD FOR THE PRODUCTION OF 17 ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE, AND MEGESTROL ACETATE | BAYER SCHERING PHARMA AG (DE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080269140-A1 | Conformationally Constrained Smac Mimetics and the Uses Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2002026325-A9 | RESTORATION OF PERTURBED BARRIER FUNCTION BY APPLICATION OF ANTIANDROGENS | UNIV CALIFORNIA (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002026325-A2 | RESTORATION OF PERTURBED BARRIER FUNCTION BY APPLICATION OF ANTIANDROGENS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-0479867-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES. | COHEN MICHAEL (NL) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991000095-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES | COHEN MICHAEL (NL) | 1991-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269140-A1 | Conformationally Constrained Smac Mimetics and the Uses Thereof | BID, API5, BIRC3 | CYP3A4 4804/4885PGR 4426/4885AR 3452/4885 |
| US-20090082445-A1 | GOSSYPOL CO-CRYSTALS AND THE USE THEREOF | BAX, BCL2, CASP8 | CYP3A4 3951/4885PGR 4476/4885AR 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.